Accure Receives CE Mark Approval for First-Ever 1726nm Laser Platform to treat Acne
By: Colorado BioScience Association Date: 05/16/2020
Groundbreaking platform combines novel laser wavelength with fully integrated tissue temperature monitoring and control systems to deliver a paradigm-shifting non-systemic solution for acne sufferers.
Accure Acne, Inc., a pioneer in innovative energy-based solutions for the acne market, today announced it has been granted the European CE mark for its groundbreaking Accure Laser™ system to treat patients with moderate acne vulgaris.1 The Accure Laser is the first commercially-developed light-based platform in the world to selectively target and injure sebaceous glands, the fundamental source of sebum production and the key to a durable solution for acne.
Learn more in the press release.